



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Anthony E. BOLTON et al.

Title: APOPTOTIC ENTITIES FOR USE  
IN TREATMENT OF  
NEURODEGENERATIVE AND  
OTHER NEUROLOGICAL  
DISORDERS

Appl. No.: 09/871,146

Filing Date: 5/25/2001

Examiner: O. Chernyshev

Art Unit: 1646

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.

*Rene Campos*

(Printed Name)

*Rene Campos*

(Signature)

11/18/05

(Date of Deposit)

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO-1449 is a listing of a document known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to

antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed document is being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

**RELEVANCE OF EACH DOCUMENT**

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

**FEE**

A fee in connection with submission of a supplemental information disclosure statement under 37 CFR §1.97(c) in the amount of \$180.00 in accordance with 37 CFR §1.17(p) is attached.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even

entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

Date 18-Jan-05

By Stephen Todd

Stephen Todd  
Agent for Applicant  
Registration No. 47,139

FOLEY & LARDNER LLP  
Customer Number: 38706  
Telephone: (650) 251-1155  
Facsimile: (650) 856-3710



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Anthony E. BOLTON et al.

Title: APOPTOTIC ENTITIES FOR USE  
IN TREATMENT OF  
NEURODEGENERATIVE AND  
OTHER NEUROLOGICAL  
DISORDERS

Appl. No.: 09/871,146

Filing Date: 5/25/2001

Examiner: O. Chernyshev

Art Unit: 1646

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.

*Rene Campos*

(Printed Name)

(Signature)

*11/18/05*

(Date of Deposit)

**TRANSMITTAL**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents in the above-referenced application:

1. Supplemental Information Disclosure Statement (3 pgs.);
2. PTO Form 1449 (1 pg.);
3. One (1) references as cited on Form 1449 as C-1; and
4. Return postcard

A check in the amount of \$1800 is enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed

herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872. If any extensions of time are needed for timely acceptance of papers submitted herewith, applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 50-0872.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date 18-Jan-05

By 

Stephen Todd  
Agent for Applicant  
Registration No. 47,139

FOLEY & LARDNER LLP  
Customer Number: 38706  
Telephone: (650) 251-1155  
Facsimile: (650) 856-3710

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 355908-3053	SERIAL NO. 09/871,146
INFORMATION DISCLOSURE CITATION  (Use several sheets if necessary)		APPLICANT Anthony E. BOLTON et al.		
		FILING DATE 5/25/2001	GROUP ART UNIT 1646	

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							YES NO

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

C1	Marina, et al. "Apoptosis of Human Lymphocytes in the Absence or Presence of Internucleosomal DNA Cleavage" <i>Biochemical and Biophysical Research Communications</i> 229:910-915 (1996)				

EXAMINER	DATE CONSIDERED

\* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.